DERMATA THERAPEUTICS INC (DRMA) Fundamental Analysis & Valuation

NASDAQ:DRMA • US2498455045

Current stock price

1.22 USD
+0.02 (+1.67%)
Last:

This DRMA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. DRMA Profitability Analysis

1.1 Basic Checks

  • DRMA had negative earnings in the past year.
  • In the past year DRMA has reported a negative cash flow from operations.
  • In the past 5 years DRMA always reported negative net income.
  • DRMA had a negative operating cash flow in each of the past 5 years.
DRMA Yearly Net Income VS EBIT VS OCF VS FCFDRMA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -2M -4M -6M -8M -10M

1.2 Ratios

  • With a Return On Assets value of -174.46%, DRMA is not doing good in the industry: 87.07% of the companies in the same industry are doing better.
  • DRMA's Return On Equity of -223.42% is on the low side compared to the rest of the industry. DRMA is outperformed by 70.27% of its industry peers.
Industry RankSector Rank
ROA -174.46%
ROE -223.42%
ROIC N/A
ROA(3y)-194.6%
ROA(5y)-241.76%
ROE(3y)-356.45%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
DRMA Yearly ROA, ROE, ROICDRMA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 1K -1K 2K

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for DRMA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
DRMA Yearly Profit, Operating, Gross MarginsDRMA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. DRMA Health Analysis

2.1 Basic Checks

  • The number of shares outstanding for DRMA has been increased compared to 1 year ago.
  • The number of shares outstanding for DRMA has been increased compared to 5 years ago.
  • There is no outstanding debt for DRMA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
DRMA Yearly Shares OutstandingDRMA Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 50K 100K 150K 200K 250K
DRMA Yearly Total Debt VS Total AssetsDRMA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M

2.2 Solvency

  • Based on the Altman-Z score of -23.12, we must say that DRMA is in the distress zone and has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of -23.12, DRMA is doing worse than 85.33% of the companies in the same industry.
  • DRMA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -23.12
ROIC/WACCN/A
WACCN/A
DRMA Yearly LT Debt VS Equity VS FCFDRMA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 5M -5M 10M -10M

2.3 Liquidity

  • A Current Ratio of 4.56 indicates that DRMA has no problem at all paying its short term obligations.
  • DRMA has a Current ratio (4.56) which is in line with its industry peers.
  • A Quick Ratio of 4.56 indicates that DRMA has no problem at all paying its short term obligations.
  • The Quick ratio of DRMA (4.56) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 4.56
Quick Ratio 4.56
DRMA Yearly Current Assets VS Current LiabilitesDRMA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. DRMA Growth Analysis

3.1 Past

  • DRMA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 82.70%, which is quite impressive.
EPS 1Y (TTM)82.7%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%91.91%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • Based on estimates for the next years, DRMA will show a very strong growth in Earnings Per Share. The EPS will grow by 40.71% on average per year.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y94.68%
EPS Next 2Y40.71%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
DRMA Yearly EPS VS EstimatesDRMA Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 -2K -4K -6K

More info and screens

Find the best growth stocksShow best growing peers

1

4. DRMA Valuation Analysis

4.1 Price/Earnings Ratio

  • DRMA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for DRMA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
DRMA Price Earnings VS Forward Price EarningsDRMA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
DRMA Per share dataDRMA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -10 -20

4.3 Compensation for Growth

  • A more expensive valuation may be justified as DRMA's earnings are expected to grow with 40.71% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y40.71%
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. DRMA Dividend Analysis

5.1 Amount

  • DRMA does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

DRMA Fundamentals: All Metrics, Ratios and Statistics

DERMATA THERAPEUTICS INC

NASDAQ:DRMA (3/17/2026, 4:00:00 PM)

1.22

+0.02 (+1.67%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-14
Earnings (Next)03-17
Inst Owners5.32%
Inst Owner Change-74.59%
Ins Owners35.66%
Ins Owner Change3.58%
Market Cap2.92M
Revenue(TTM)N/A
Net Income(TTM)-8.85M
Analysts82.86
Price Target10.2 (736.07%)
Short Float %8.59%
Short Ratio0.07
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)21.07%
Min EPS beat(2)-1.74%
Max EPS beat(2)43.88%
EPS beat(4)2
Avg EPS beat(4)2.37%
Min EPS beat(4)-34.64%
Max EPS beat(4)43.88%
EPS beat(8)4
Avg EPS beat(8)8.9%
EPS beat(12)8
Avg EPS beat(12)13.54%
EPS beat(16)12
Avg EPS beat(16)15.45%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.74
P/tB 0.74
EV/EBITDA N/A
EPS(TTM)-28.41
EYN/A
EPS(NY)-3.07
Fwd EYN/A
FCF(TTM)-3.91
FCFYN/A
OCF(TTM)-3.91
OCFYN/A
SpS0
BVpS1.66
TBVpS1.66
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -174.46%
ROE -223.42%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-194.6%
ROA(5y)-241.76%
ROE(3y)-356.45%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.56
Quick Ratio 4.56
Altman-Z -23.12
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)82.7%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%91.91%
EPS Next Y94.68%
EPS Next 2Y40.71%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y21.32%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-31.82%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-31.82%
OCF growth 3YN/A
OCF growth 5YN/A

DERMATA THERAPEUTICS INC / DRMA Fundamental Analysis FAQ

What is the ChartMill fundamental rating of DERMATA THERAPEUTICS INC (DRMA) stock?

ChartMill assigns a fundamental rating of 2 / 10 to DRMA.


What is the valuation status for DRMA stock?

ChartMill assigns a valuation rating of 1 / 10 to DERMATA THERAPEUTICS INC (DRMA). This can be considered as Overvalued.


Can you provide the profitability details for DERMATA THERAPEUTICS INC?

DERMATA THERAPEUTICS INC (DRMA) has a profitability rating of 0 / 10.


Can you provide the financial health for DRMA stock?

The financial health rating of DERMATA THERAPEUTICS INC (DRMA) is 6 / 10.


Can you provide the expected EPS growth for DRMA stock?

The Earnings per Share (EPS) of DERMATA THERAPEUTICS INC (DRMA) is expected to grow by 94.68% in the next year.